Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Cloprostenol; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol; Travoprost

Criteria

Inclusion Criteria:

• Open angle glaucoma or ocular hypertension

• Best corrected visual acuity of 20/100 or better in both eyes

Exclusion Criteria:

• Ocular surgery within 3 months, or anticipated ocular surgery within 12 weeks

• Previous treatment with LUMIGAN® RC or DuoTrav®

• History of LASIK, LASEK, RK or PRK in the study eye(s)

• Active ocular inflammation